Background: To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV. METHODS: Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay. RESULTS: During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy. CONCLUSIONS: In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B / P. Lampertico, M. Viganò, F. Facchetti, F. invernizzi, A. Aroldi, G. Lunghi, P. Messa, M. Colombo. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 26:6(2011 Jun), pp. 2037-2041.
Titolo: | Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B |
Autori: | LAMPERTICO, PIETRO (Primo) COLOMBO, MASSIMO GIUSEPPE (Ultimo) |
Parole Chiave: | adefovir dipivoxil; hepatitis B virus; lamivudine-resistance; renal transplantation |
Settore Scientifico Disciplinare: | Settore MED/12 - Gastroenterologia |
Data di pubblicazione: | giu-2011 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1093/ndt/gfr174 |
Appare nelle tipologie: | 01 - Articolo su periodico |